

Special Issue

Innovations Advancing Vaccine Preparedness and Response Capabilities to Counter Pandemic Influenza

Message from the Guest Editor

The following Special Issue invites original contributions that propose or demonstrate innovations across the entire target product profile of candidate influenza vaccines. These innovations aim to surpass currently available vaccines in key metrics such as efficacy, durability, breadth of protection, development speed, adaptability, and ease of administration. We are particularly interested in novel vaccine candidates leveraging "platform technologies" (e.g., nucleic acid, recombinant proteins, and viral vectors) that can significantly expedite the development timeline for pandemic vaccines from initial sequence identification to regulatory approval and mass deployment. We welcome submissions covering the following topics of interest:

- New vaccine mechanisms of action, high efficacy, and safety.
- Seasonal vaccines with the potential to convey some level of immunity to an emerging zoonotic influenza virus.
- Passive immunization or Pre-Exposure Prophylaxis (PrEP) with monoclonal antibodies
- Manufacturing platform speed, yield, and capacity.
- Clinical trial acceleration and correlates of protection.
- Enabling technologies and strategies.
- Accessibility, impact, and sustainability.

Deadline for manuscript submissions

30 June 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/212128

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).